UNCY Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

6.890

Open

6.800

VWAP

6.77

Vol

488.85K

Mkt Cap

146.36M

Low

6.610

Amount

3.31M

EV/EBITDA(TTM)

--

Total Shares

21.49M

EV

102.59M

EV/OCF(TTM)

--

P/S(TTM)

--

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Show More

Events Timeline

(ET)

2026-01-29

07:20:00

Unicycive Therapeutics OLC New Drug Application Accepted by FDA

2025-12-29 (ET)

2025-12-29

07:10:00

Unicycive Therapeutics Resubmits NDA to FDA for Oxylanthanum Carbonate

2025-11-12 (ET)

2025-11-12

07:17:21

Unicycive Therapeutics projects funding to last until 2027

2025-11-12

07:17:04

Unicycive Therapeutics Announces Q3 EPS of 46c, Below Consensus Estimate of 53c

2025-10-30 (ET)

2025-10-30

07:19:23

Unicycive Therapeutics to Showcase New OLC Findings at ASN Kidney Week 2025

2025-10-28 (ET)

2025-10-28

07:09:19

Unicycive Offers Update on FDA Meeting and NDA Resubmission for OLC

News

Globenewswire

03-18Globenewswire

ASP Isotopes Class Action Survives Dismissal Motion

Globenewswire

03-16Globenewswire

ASP Isotopes Class Action Survives Dismissal Motion

Newsfilter

01-29Newsfilter

Unicycive's Drug Application Accepted by FDA with Target Date Set

seekingalpha

01-29seekingalpha

Unicycive's Kidney Disease Therapy NDA Accepted by FDA

Newsfilter

01-29Newsfilter

Unicycive's Drug Application Accepted by FDA

NASDAQ.COM

2025-12-29NASDAQ.COM

Unicycive Resubmits NDA for OLC to Treat Hyperphosphatemia in CKD Patients

5 Analyst Rating

Wall Street analysts forecast UNCY stock price to rise

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

35.80

High

60.00

Current: 0.000

Low

21.00

Averages

35.80

High

60.00

WestPark Capital

Buy

initiated

$72

AI Analysis

2026-02-19

Reason

WestPark Capital

Price Target

$72

AI Analysis

2026-02-19

initiated

Buy

Reason

WestPark Capital initiated coverage of Unicycive Therapeutics with a Buy rating and $72 price target. Given the view that a significant number of dialysis organizations are likely to switch to OLC next year, the firm calls Unicycive "a compelling investment" with a fully de-risked PDUFA on June 29, market launch of "a best-in-class drug" in Q3 of 2026, and TDAPA reimbursement support likely beginning on January 1, 2027. The firm anticipates "significant" stock appreciation ahead of likely approval, the analyst added.

H.C. Wainwright

H.C. Wainwright

NULL -> Buy

maintain

$9 -> $22

2025-10-29

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$9 -> $22

2025-10-29

maintain

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Unicycive Therapeutics to $22 from $9 and keeps a Buy rating on the shares. The believes the company's regulatory overhang has been revolved after its Type A meeting with the FDA. Unicycive plans to file a response to the complete response letter by year-end and expects a decision in the first half of 2026, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for UNCY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Unicycive Therapeutics Inc (UNCY.O) is 1.59, compared to its 5-year average forward P/E of -0.46. For a more detailed relative valuation and DCF analysis to assess Unicycive Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.46

Current PE

1.59

Overvalued PE

6.55

Undervalued PE

-7.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-6055.47

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

22432.39

Undervalued EV/EBITDA

-34543.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

4.42

Current PS

1.12

Overvalued PS

16.53

Undervalued PS

-7.69

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

most bullish ticker next 6 months

Intellectia · 10 candidates

Analyst Consensus: Strong BuyQuarter Eps Yoy Growth: >= 20.0%Target Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200One Month Predict Return: >= 8.0%

Ticker

Name

Market Cap$

Spyre Therapeutics Inc

2.93B

Geron Corp

1.23B

Aviat Networks Inc

314.56M

Owlet Inc

309.45M

Viridian Therapeutics Inc

2.68B

Unicycive Therapeutics Inc

139.91M

low float high volume

Intellectia · 49 candidates

Region: USVolume: >= 500,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000

Ticker

Name

Market Cap$

FAT Brands Inc

5.25M

Aprea Therapeutics Inc

5.57M

FAT Brands Inc

27.81M

cbdMD Inc

10.92M

Lixiang Education Holding Co Ltd

6.50M

Kaixin Holdings

29.77M

best strong buy for today

Intellectia · 86 candidates

Analyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Cingulate Inc

43.41M

Perspective Therapeutics Inc

261.77M

Enliven Therapeutics Inc

1.51B

ADTRAN Holdings Inc

757.90M

Universal Technical Institute Inc

1.52B

Centessa Pharmaceuticals PLC

3.82B

Whales Holding UNCY

Vivo Capital, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Unicycive Therapeutics Inc (UNCY) stock price today?

The current price of UNCY is 6.81 USD — it has increased 0.74

What is Unicycive Therapeutics Inc (UNCY)'s business?

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

What is the price predicton of UNCY Stock?

Wall Street analysts forecast UNCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNCY is35.80 USD with a low forecast of 21.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Unicycive Therapeutics Inc (UNCY)'s revenue for the last quarter?

Unicycive Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Unicycive Therapeutics Inc (UNCY)'s earnings per share (EPS) for the last quarter?

Unicycive Therapeutics Inc. EPS for the last quarter amounts to -0.33 USD, decreased -28.26

How many employees does Unicycive Therapeutics Inc (UNCY). have?

Unicycive Therapeutics Inc (UNCY) has 22 emplpoyees as of March 20 2026.

What is Unicycive Therapeutics Inc (UNCY) market cap?

Today UNCY has the market capitalization of 146.36M USD.